Epilepsy Webinars 2020| Epilepsy Online Events| Epilepsy Treatment Webinar| Epilepsy Seizures Live Events| Neurology Online Webinar| Scientific Webinar on Epilepsy | Europe | USA | Middle East

Theme: Impact of COVID-19 on management of Epilepsy

Epilepsy 2020

Scientific Program

Renowned Speakers

Jeffrey M. Chung
Cedars-Sinai Medical Center
USA

Sharon Ceanna Fernando
Syneos Health
USA

Michele Roccella
University of Palermo
Italy

Long-Jun Wu
Mayo Clinic
USA

Ann Hanafy
Cairo University
Egypt

Joey Gaines
USA
USA

Marco Carotenuto
University of Campania "Luigi Vanvitelli"
Italy

Yo-Tsen Liu
National Yang-Ming University
Taiwan

Ramon Bautista
University of Florida HSC Jacksonville
USA

Alcibiades J. Rodriguez
NYU School of Medicine
USA

Alain L Fymat
International Institute of Medicine and Science
USA

Rapita Naresh Sood
McGill University
Canada

Alberto Musto
Eastern Virginia Medical School
USA

Tomokatsu Hori
Tokyo University
Japan

Leon Isaemidis
Louisiana Tech University
USA

Mootaz Salman
Shefield Hallam University
UK

M. M. Khan
Scientist,Univ. of Iowa Hospitals and Clinics
USA

Daqing
Imperial College London
UK

George Perry
The University of Texas
USA

Yawu Liu
Kuopio Univ. Hospital
Finland

Jennifer DeFeo
Chicago School of Prof.Psychology
USA

Kurt Jellinger
Inst. of Clinical Neurobiology
Austria

Guy H Fontaine
HÃ´pital de la SalpÃªtriÃ¨re
France

Kuldip Sidhu
Cell Therapeutics Pty Ltd
Australia

Fabio Grizzi
Laboratory of Molecular Gastroenterology of the Humanitas Clinical and Research Center
Italy

William Cho
Queen Elizabeth Hospital
Hong Kong

Xin Wang
Harvard Medical School
USA

Lucia M. Vaina
Massachusetts Gen. Hosp.
USA

Zameel Cader
Nuffield college
UK

Tang Wai Kwong
Shatin Hospital Hong Kong
Hong Kong

Davide Moretti
National Institute of Research and Cure for Mental disorders and Dementia
Italy

Dhavendra Kumar
University Hospital of Wales
UK

Chethan P. V. Rao
Baylor College of Medicine
USA

Martina Bebin
UAB Epilepsy Center
USA

O. Nuri Ozgirgin
Proffessor Bayindir Hospital
Turkey

Insop Shim
Kyung Hee University
South Korea

Xavier F Figueroa
Pontifical Catholic University
Chile

Peter Silburn
The University of Queensland
Australia

Galina Mindlin
Mount Sinai
USA

Bibiana Bielekova
National Institutes of Health
USA

Allal Boutajangout
New York University Langone Medical Center
USA

Giulio Maria Pasinetti
Icahn School of Medicine at Mount Sinai
USA

Karolina Can
University in GÃ¶ttingen
Germany

Fares Nigim
Harvard Medical School
USA

Zoi A Giavri
Advantis Medical Imaging
Greece

Adam Mate
Stroke Association
Australia

Malcolm Hooper Oxymed
Australia Austra Oxymed
Australia

Judit Subirana-Mirete
Ramon Llull University
Spain

Selma Pelaez
Selma Pelaez UManresa-FUB
Spain

Isabel Lastres-Becker
Autonomous University of Madrid
Spain

Anthony E Kline
University of Pittsburgh
USA

Evelyn M Garcia
Carilion Clinic
USA

Ann Marie Gillie
Democratic Republic of the Congo
South Africa

Galia Valentinova Anguelova
Leiden University Medical Centre
Netherlands

Parreira M
University of Minho
Portugal

Maia Machvariani-Tsereteli
Ivane Javakhisvili Tbilisi State University
Georgia

Yuri P Danilov
University of Wisconsin-Madison
USA

FrÃ©dÃ©ric Haesebaert
Lyon Neuroscience Research Center
France

Shao-Jun Tang
University of Texas
USA

Wolfram Kersten
Mind-up GmbH & CO.KG â€“ Bamberg
Germany

Trevor Archer
University of Gothenburg
Sweden

Suresh Kumar
Director TBI & Memory Research Institute & Regain Memory Center
USA

Charles W Graham
Community College of Aurora
USA

Adinda Prawityasari Kusubandio
KAPETA Foundation
Indonesia

Peter Poortvliet
University of Queensland
Australia

Amir Tamiz
National Institute of Health
USA

Frank Galimidi
New Beginnings Recovery Center
USA

Konstantin Slavin
University of Illinois
USA

Peter Kaplan
Johns Hopkins University
USA

Lucia M. Vaina
Boston University College of Engineering
USA

Markku Kurkinen
Wayne State University School of Medicine
USA

Deborah Oliveira
University of Nottingham
UK

Diana Kljenak
Ontario Psychiatric Association
Canada

Wen-Hai Chou
National Health Research Institute
Taiwan

Ljudmila Stojanovich
Belgrade University
Serbia

Felipe Padilla Vazquez
Vascular and Endovascular Center
Mexico

David Truswell
Culture Dementia
UK

Walter E. Muller
University of Frankfurt
Germany

Alok Sharma
NeuroGen Brain & Spine Institute
India

Safa Shehab
UAE University
UAE

Fan Fan
University of Mississippi Medical Center
USA

Regina Esiovwa Ahumareze
University of the West of Scotland
UK

Bo Feng
University of Hong Kong
Hong Kong

Susan Hosseini Nasab
The University of Texas Health Science Center
USA

Sybille Krauss
Neurodegenerative Erkrankungen
Germany

Haifa Al Issa
King Saud bin Abdulaziz University for Health Sciences
Saudi Arabia

Francesco Massari
University of Massachusetts Medical School
USA

Mohamed A Fahmy Zeid
Alexandria University
Egypt

Ute-Christiane Meier
Queen Mary University London
UK

James Gratwicke
The National Hospital for Neurology and Neurosurgery
UK

Roberto Cartolari
Regional Hospital of Bellinzona and Valleys San Giovanni
Switzerland

Giovanni Antioco Putzu
Casa di Cura Santâ€™Elena
Italy

Kay Ohlendieck
Maynooth University
Ireland

Eef Hogervorst
Loughborough University
UK

Joanna B. Strosznajder
Polish Academy of Sciences
Poland

Felix-Martin Werner
Euro Academy Pobneck
Germany

Marina Zueva
Moscow Helmholtz Research Institute of Eye Diseases Russian Federation
Russia

Chan Kam Tim Michael
Association of Integrative Aesthetic Medicine
Hong Kong

Arunkumar Umesh Prasadagic
Taishan Medical University
China

Hans von Holst
Royal Institute of Technology
Sweden

Epilepsy 2020

Epilepsy 2020 welcomes attendees, participants, students, speakers, organizing committee members, delegates from all over the world. We welcome you and appreciate your participation at the 6^th International Conference on Epilepsy & Treatment, which is going to be held during September 21, 22, 2020 is a Webinar event and it will be organized around the theme " Impact of COVID-19 on management of Epilepsy" which includes prompt Keynote presentations, Oral talks, Poster presentations and Exhibitions.

We organize a series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Why to Attend?

Epilepsy 2020 is the gathering of Scientists, Neurologists, speakers, professors, business delegates and students all over the world to participate to discover the new novel therapeutics of Epilepsy, where people can get desired knowledge over Epilepsy and recent inventions on Epilepsy Treatment. We are glad to invite you at Epilepsy 2020 where you can experience a really sumptuous information and knowledge on Epilepsy management.

Importance and Scope:

Epilepsy is a chronic disorder usually occurred in children and people aged above 60 years. A neurological disorder marked by sudden recurrent episodes of seizures with loss of consciousness. It is associated with abnormal electrical activity in the brain with the loss of consciousness; it may be of different types and with different episodes of seizures from person to person. Epilepsy is a non-communicable disease with approximately 50 million people in the world suffers from this disease. People with Epilepsy respond to treatment approximately within 70% of the time. About three-fourths of people with Epilepsy living in low- and middle- income countries do not get the treatment properly as they need. In many parts of the world, people with Epilepsy and their families suffer from stigma and discrimination. It is estimated that every year nearly 2.4 million people are diagnosed with Epilepsy and there are 4 to 5 in a group of 1000 people with active Epilepsy. Nearly 80% of the individuals with Epilepsy are found in developing regions.

Young Research’s Awards at Epilepsy 2020

Epilepsy 2020 is intended to honour prestigious award for talented Young researchers, Scientists, Young Investigators, Post-Graduate students, Post-doctoral fellows, Trainees, junior faculty in recognition of their outstanding contribution towards the conference theme. The Young Scientist Awards make every effort in providing a strong professional development opportunity for early career academicians by meeting experts to exchange and share their experiences on all aspects of Neurology.

Young Research’s Awards at Epilepsy 2020 for the Nomination:

Young Researcher Forum - Outstanding Masters/Ph.D./Post Doctorate thesis work Presentation and only 25 presentations acceptable at the Epilepsy 2020.

YRF Registration benefits:

Our conferences provide best Platform for your research through oral presentations.

Share the ideas with both eminent researchers and mentors.

Young Scientist Award reorganization certificate and memento to the winners

Young Scientists will get appropriate and timely information by this Forum.

Platform for collaboration among young researchers for better development

Award should motivate participants to strive to realize their full potential which could in turn be beneficial to the field as whole.

YRF Registration Deadline:

Till May 28, 2020– $399

Till June 28, 2020– $499

Till September 21, 2020– $599

Target Audience:

Neurosurgeons Specializing in Epilepsy

Epilepsy nurse specialists

Child life specialists

Pharmaceutical Industries

Researchers in Epilepsy

Epilepsy Foundations

Epilepsy Diagnosis Centres

Conference Opportunities:

Speaker Presentations

Poster Display

Symposium hosting (4-5 member teams)

Workshop organizing

For Researchers and Faculty Members

For Universities, Associations & Societies:

Association Partnering

Collaboration proposals

Academic Partnering

Group Participation

For Students and Research Scholars:

Poster Competition (Winner will get Best Poster Award)

Young Researcher Forum (YRF Award to the best presenter)

Student Attendee

Group Registrations

For Business Delegates:

Speaker Presentations

Symposium hosting

Book Launch event

Networking opportunities

Audience participation

For Product Manufacturers:

Exhibitor and Vendor Booths

Sponsorships opportunities

Product launch

Workshop organizing

Scientific Partnering

Marketing and Networking with clients

We cordially invite all the participants who are interested in sharing their knowledge and research in the area of Epilepsy & Neurology. Epilepsy 2020 deliberates thought provoking Keynote lectures, Oral Presentations, Poster Presentations, Workshops, Symposiums and Exhibition by the worldwide researchers.

Highlights of Epilepsy 2020 Conference

Session on EPILEPSY AND TYPES OF SEIZURES

Epilepsy is a chronic noncommunicable and Neurological disorder of the brain that affects people of all ages. Epilepsy occurs when brain activity becomes abnormal, causing seizures. Seizures can affect any process your brain coordinates. Around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally.

6^th International Conference on Epilepsy & Treatment, September 20-21, 2020; 30th International Conference on Neurology and Cognitive Neuroscience, February 24-25, 2020 London, UK; 6^th World congress on Parkinsons & Huntington Disease, September 20-21, 2019 ; 24^th International Conference on Neurology & Neurophysiology, March 16-17, 2020 Berlin, Germany; 34^th European Neurology Congress, June 24-25, 2020 Zurich, Switzerland; 8^th International Conference on Brain Disorders and Therapeutics, August 21-22, 2020 Paris, France.

Session on NEUROBIOLOGY OF EPILEPSY

Epilepsy is a chronic disorder with diverse clinical characteristics that preclude a singular mechanism a neurological disorder marked by sudden recurrent episodes of seizures. A seizure occurs when part of the brain receives a burst of abnormal electrical signals that temporarily interrupts normal electrical brain function. It is one of the most common disorders of the nervous system and affects people of all ages, races, and ethnic background. The fact that multiple mechanisms exist is not surprising given the varied ways the normal nervous system controls this balance. In contrast, understanding seizures in brain of an individual with epilepsy is more difficult because seizures are typically superimposed on an altered nervous system.

6^th International Conference on Epilepsy & Treatment, September 20-21, 2020; 30^th International Conference on Neurology and Cognitive Neuroscience, February 24-25, 2020 London, UK; 6^th World congress on Parkinsons & Huntington Disease, September 20-21, 2019 ; 24^th International Conference on Neurology & Neurophysiology, March 16-17, 2020 Berlin, Germany; 34^th European Neurology Congress, June 24-25, 2020 Zurich, Switzerland; 8^th International Conference on Brain Disorders and Therapeutics, August 21-22, 2020 Paris, France.

Session on EPILEPTOGENESIS

Epileptogenesis is the chronic process by which a normal brain develops epilepsy. Epilepsy is a chronic condition in which seizures occur. These changes to the brain occasionally cause neurons to fire in a hyper-synchronous manner, known as a seizure. Epileptogenesis can be triggered by genetic or acquired factors, and that can continue long after epilepsy diagnosis.

Session on EPILEPSY IN PEDIATRICS

Epilepsy can begin at any time of life, but it is most commonly diagnosed in children and people over the age of 65. More than half of children with epilepsy will outgrow their seizures as they mature, while others may have seizures that continue into adulthood. Although epilepsy varies from person to person, children with epilepsy generally have seizures that respond well to medication. Epilepsy affects around 1 in every 200 children and young people under 18 Children having idiopathic. About two-thirds of all children with epilepsy outgrow their seizures by the time they are teenagers. However, it is important for parents to help their child maintain a healthy lifestyle and ensure regular medical visits.

Febrile convulsions
Childhood absence epilepsy
Epilepsy in gender & age
Seizures in childhood
Attention Deficit Hyperactivity Disorder (ADHD)

Session on EPILEPSY & PREGNANCY

Women with epilepsy have a number of unique concerns during pregnancy. Pregnant women with epilepsy constitute 0.5% of all pregnancies. Some antiepileptic drugs considered safe to the foetus may be associated with increased risk of seizures and maternal mortality. Factors such as epilepsy, anticonvulsant-induced teratogenicity, patient's genetic predisposition and the severity of convulsive disorder may attribute to adverse pregnancy outcome for the children of women with epilepsy.

Session on EPILEPSY SURGERY

Medications can control seizures in most people with epilepsy, but they don’t work for everyone. About 30% of people taking the drugs can’t tolerate the side effects. A person's type of seizures and where they begin in the brain are key to deciding what kind of surgery may help. Surgery has three main goals, they are Remove the area of the brain that causes seizures, Disrupt the nerve pathways that seizure impulses take through your brain, Implant a device to treat epilepsy. An operation on the brain can control seizures and improve your quality of life.

Session on EPILEPSY DEVICES

Seizure medicines do not control seizures or can cause bothersome side effects in at least 3 out of 10 people with epilepsy. Seizure alert devices are useful in letting family members know if a seizure is occurring, especially parents of young children. The devices can notify nearby family or caregivers when a seizure occurs through alarms, phone calls or text alerts, depending on the device. They may also be able to give rescue medications or call for an ambulance if the seizure lasts too long or the person has repeated seizures.

Session on ADVANCED EPILEPSY DIAGNOSIS ASSESSMENT

Doctors have developed when an individual experience a seizure for the first time doctors advices him for EEG and observes for abnormality in the of EEG these tests differentiate patient from epileptic to non- epileptic .Research suggests that patients are only suggested to medicated for epilepsy only after their occurrence of second seizure. Many non-epileptic patients experience an unusual brain activity so; it is advised to record EEG while sleeping is preferable. Brain scans like CT- SCAN are used.

6^th International Conference on Epilepsy & Treatment, September 20-21, 2020; 30^thInternational Conference on Neurology and Cognitive Neuroscience, February 24-25, 2020 London, UK; 6^th World congress on Parkinsons & Huntington Disease, September 20-21, 2019 ; 24^th International Conference on Neurology & Neurophysiology, March 16-17, 2020 Berlin, Germany; 34^th European Neurology Congress, June 24-25, 2020 Zurich, Switzerland; 8^th International Conference on Brain Disorders and Therapeutics, August 21-22, 2020 Paris, France.

Session on SEIZURE FIRST AID AND SAFETY

Epilepsy is a common condition of the brain in which a person has a tendency to have recurrent unprovoked seizures. About 1 out of 10 people may have a seizure during his or her lifetime. Safety precautions should be sensible and relevant to the person, with a balance between risk and restrictions. That means seizures are common, and one day you might need to help someone during or after a seizure. First aid for seizures is aimed at keeping the person safe until the seizure stops on its own.

Session on SUDEP: SUDDEN UNEXPLAINED DEATH IN EPILEPSY

Sudden Unexpected Death in Epilepsy (SUDEP) is a fatal complication of epilepsy. SUDEP accounts for 7–17% of deaths among people with epilepsy. This is the leading cause of death in people with uncontrolled seizures. Patients with uncontrolled seizures are at greatest risk for SUDEP, and experiencing tonic-clonic seizures, taking multiple antiepileptic drugs and having coexisting neurologic disease further increase the risk.

6^th International Conference on Epilepsy & Treatment, September 20-21, 2020 ; 30^th International Conference on Neurology and Cognitive Neuroscience, February 24-25, 2020 London, UK; 6^th World congress on Parkinsons & Huntington Disease, September 20-21, 2019 ; 24^th International Conference on Neurology & Neurophysiology, March 16-17, 2020 Berlin, Germany; 34^th European Neurology Congress, June 24-25, 2020 Zurich, Switzerland; 8^th International Conference on Brain Disorders and Therapeutics, August 21-22, 2020 Paris, France.

Session on CANNABINOIDS IN TREATMENT OF RESISTANT EPILEPSY

The interest in Cannabis-based products for the treatment of refractory epilepsy has skyrocketed in recent years. Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequately powered Placebo-controlled, Randomized trials (RCTs) with Cannabidiol (CBD), a cannabis derivative.

Session on METACOGNITIVE BELIEFS IN EPILEPSY

Emotional distress is common in people with epilepsy (PWE) for which efficacious interventions are required. Developing evidence-based treatments should be based on testable models of the psychological mechanisms maintaining Psychopathology. The Self-Regulatory Executive Function (S-REF) model proposes that maladaptive Metacognitive beliefs and processes are central to the development and maintenance of emotional distress. Although preliminary support exists for the role of metacognitive beliefs in emotional distress in PWE, their role has yet to be tested when controlling for the contribution made by illness perceptions.

Session on COGNITIVE DISORDERS OF EPILEPSY

Cognitive disorders are common in patients with epilepsy. Their aetiology is multifactorial, being affected by the type and location of the epileptogenic lesion, Epileptic syndrome, type of seizures, and age of onset, frequency and severity. Timely diagnosis and treatment can help to reduce their impact on the patient's quality of life.

Temporary confusion
A Staring Spell
Uncontrollable jerking movements of the arms and legs
Loss of consciousness or awareness

Session on PREVENTION & MANAGEMENT OF EPILEPSY

Preventing seizures and other problems must be part of seizure management. This means working together with your health care team to control seizures as best as possible. Maintaining Ketogenic diet, regular exercise can reduce the risk of Epilepsy, get plenty of sleep during nights and avoid using drugs and alcohol, taking seizure medicines regularly as problems taking medicines is one of the biggest risks for uncontrolled seizures. Epilepsy due to medication can be subsided by discontinuing the medicines, controlling stress, anxiety & other emotional issues can reduce the risk of Epilepsy. People can also adjust their lifestyle and environment to reduce the chance of seizures.

Session on KETOGENIC DIET

The Ketogenic Diet (KD) is a modality of treatment used since the 1920s as a treatment for intractable epilepsy. The Ketogenic diet is a special high-fat, low-carbohydrate diet that helps to control seizures in some people with epilepsy. It is usually used in children with seizures that do not respond to medications. Evidence shows that KD and its variants are a good alternative for non-surgical pharmacoresistant patients with epilepsy of any age.

Session on NON-SURGICAL TREATMENT OF EPILEPSY

Epilepsy treatment has been applied to treat patients with intractable epilepsy for decades that are not controlled by neither antiepileptic drugs (AEDs) nor surgical candidates. If Antiepileptic drugs aren't controlling your seizures and brain surgery isn't suitable for you, there are other procedures that could help to control Epileptic Seizures.

Session on HERBAL TREATMENTS FOR EPILEPSY

Before modern seizure medicines were developed, people with epilepsy and their doctors looked for a remedy in various herbs and combinations of herbs. Good news is, there are some natural remedies for seizures. Before advanced seizure medications were even discovered, doctors used herbs to treat this condition. Herbs for seizures are still used today because of their impressive effectiveness.

Session on HOMEOPATHIC TREATMENT OF EPILEPSY

Epilepsy can be treated in a number of ways. One of the most preferred forms of treatment is Homeopathy. Homeopathy addresses both the physical symptoms of the disease and the underlying factors triggering it. Another big advantage of homeopathic treatment is that it has negligible side effects.

Session on IMMUNOMODULATORY TREATMENTS IN EPILEPSY

The role of Immunity and Inflammation appears to be an integral part of the pathogenic processes associated with some seizures, particularly with refractory epilepsy. Prompt treatment with Immunotherapy may lead to better outcomes. Immune treatment options for treatment of epilepsy include therapies such as corticosteroids, Immunoglobulin’s, Plasmapheresis, or steroid-sparing drugs such as azathioprine.

6^th International Conference on Epilepsy & Treatment, September 20-21, 2020; 30^thInternational Conference on Neurology and Cognitive Neuroscience, February 24-25, 2020 London, UK; 6^th World congress on Parkinsons & Huntington Disease, September 20-21, 2019 ; 24^th International Conference on Neurology & Neurophysiology, March 16-17, 2020 Berlin, Germany; 34^th European Neurology Congress, June 24-25, 2020 Zurich, Switzerland; 8^th International Conference on Brain Disorders and Therapeutics, August 21-22, 2020 Paris, France.

Session on EPILEPSY THERAPEUTICS & DRUG THERAPY

Zonisamide Ethosuximide is now available as rectal gel so that can be applied by family members for prolonged seizures. Drug combination sometimes lead to adverse effects like fatigue and loss of appetite so, combinations are often replaced by Monotherapy, unless monotherapy achieves desired results. When medication doesn’t achieve the required targets doctor can sometimes suggest for surgery 64% cases showed seizure free cases who undergone surgery.

Session on HIGHLY MARKETED AND USED DRUGS FOR EPILEPSY

The global market for Antiepileptic drugs is driven by advancement in drugs modification. Over the past several periods, the number of available Antiepileptic drugs has more than doubled. Many of the presently available Antiepileptic drugs have basics pharmacokinetics and more small effects on liver metabolism that converts into a lower rate of side effects, The antiepileptic drug market is threatened by generic competition, which has risen dramatically in the face of patent expirations among various major branded Antiepileptic drugs. These are the major restraints for the Global antiepileptic drugs market.

Session on EPILEPSY LINK WITH NEUROLOGICAL DISORDERS

The epilepsies have many possible causes, but for up to half of people with epilepsy a cause is not known. In other cases, the epilepsies are clearly linked to genetic factors, developmental brain abnormalities, infection, traumatic brain injury, stroke, brain tumors, or other identifiable problems.

Session on EPILEPSY AND PSYCHOLOGICAL DISORDERS

Epilepsy is not a mental illness. In fact, the vast majority of people living with epilepsy have no cognitive or psychological problem. For the most part, psychological issues in epilepsy are limited to people with severe and uncontrolled epilepsy.

Session on EPILEPSY CASE REPORTS

According to WHO, It is estimated that every year nearly 2.4 million people are diagnosed with Epilepsy and there are 4 to 5 in a group of 1000 people with active Epilepsy. Nearly 80% of the individuals with Epilepsy is found in developing regions, Epilepsy represents 0.6%, of the worldwide weight of sickness.

North America is the largest market for anti-epileptic drugs manufacturing, accounting for 33.9% of the global market. It is followed by the Asia-Pacific region and Western Europe. Eastern Europe is expected to witness the fastest market growth, with CAGR of 5.4% through 2022. Second-generation anti-epileptic drugs accounted for the largest share of the market in 2017 at 44.3%. The highest growth is projected to come from third-generation antiepileptic drugs, which are forecasted to grow at a CAGR of 3.1%.

The global epilepsy drugs market is primarily driven by the need of effective medications as the generic or branded drugs available in the market only provide symptomatic treatment. This has increased investment in the R&D of new drugs for epilepsy by companies such as Major players in the market include Pfizer Inc., UCB Biosciences Inc., GlaxoSmithKline PLC, Sanofi, Eisai Inc., Otsuka Pharmaceutical LTD., H. Lundbeck, Sumitomo Dainippon Pharma Co., Shire PLC., Marinus Pharmaceuticals, SAGE Therapeutics, H.Lundbeck, and CURx Pharmaceuticals.

Importance and Scope

Epilepsy medications can prevent seizures. An epileptic seizure is caused by hyperactivity in the brain's nerve cells. Anti-epileptic drugs (AEDs) work by lowering this level of activity. Although AEDs do not cure the underlying causes of epilepsy, they can lower the risk of seizures. But they do not work in everyone. It is sometimes possible for people to stop taking medication if they haven't had a seizure for several years. The aim of drug treatment is to prevent epileptic seizures. If this is not possible, then the goal is to at least reduce the number of seizures.

Drug treatment helps to permanently prevent seizures in most people who have epilepsy. About 5 out of 10 people stop having seizures or have fewer seizures after taking the first drug they try. Overall, about 7 out of 10 people with epilepsy have no more seizures when they use medication. The 6 million people with epilepsy in Europe want to bring epilepsy “out of the shadows”.

Research related to epilepsy is remarkably broad and comprehensive, with programs in numerous university centres worldwide. On-going studies involve many scientific disciplines and areas of exploration.

Target Audience

Doctors
Neurosurgeons Specializing in Epilepsy
Neurologists
Neuroradiologists
Neuropsychologists
EEG Technologists
Clinical Pharmacists
Epilepsy nurse specialists
Child life specialists
Directors
Pharmaceutical Industries
Pharmacists
Patients
Students
Professors
Researchers in Epilepsy
Epilepsy Foundations
Epilepsy Diagnosis Centres

Related Companies

Pfizer Inc.
UCB Biosciences Inc.
GlaxoSmithKline PLC
Sanofi
Eisai Inc.
Otsuka Pharmaceutical LTD
H. Lundbeck
Sumitomo Dainippon Pharma Co.
Shire PLC.
Marinus Pharmaceuticals
SAGE Therapeutics
H.Lundbeck
CURx Pharmaceuticals
Novartis
Elan Corporation PLC

Related Associations and Societies

The International League Against Epilepsy (ILAE)
American Epilepsy Society (AES)
National Association of Epilepsy Centers (NAEC)
International Bureau for Epilepsy
European Concerted Action and research in Epilepsy (Eucare)
Epilepsy Foundation (of America)
The Japan Epilepsy Society
Epilepsy Action Australia
Epilepsy Foundation of Victoria
Associazione Italiana Contro l’Epilessia (AICE)
The Swedish Epilepsy Association
National Society for Epilepsy
Joint Epilepsy Council (JEC) for the UK and Ireland
Indian Epilepsy Association
Rush Epilepsy Center

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	September 21-22, 2020
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1
Poster Opportunity Closed	Click Here to View